drugset / Trial / NCT03532295
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Non-randomizedSequentialOpen-labelTreatment
Summary
In this study, the investigators propose to combine retifanlimab with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM). The investigators hypothesize that this combination provides a powerful synergy between RT and immune modulators to produce more robust anti-tumor immune response, induce tumor regression and improve overall survival.
Timeline
- Start
- 2020-04-20
- Primary completion
- 2024-07-26
- Completion
- 2025-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Epacadostat | Small molecule | 400 mg | Oral |
| Subject | Retifanlimab | Monoclonal antibody | 500 mg | Intravenous |